Document is current
Any future updates will be listed below
-
Authors
Mahalingasivam, Aksayan Arunanthy https://orcid.org/0000-0003-0406-9702
Bech, Asger Ahlmann https://orcid.org/0000-0002-8281-2402
Vestergaard, Peter https://orcid.org/0000-0002-9046-2967
Jørgensen, Martin Grønbech https://orcid.org/0000-0002-3189-644X
Rasmussen, Nicklas H. https://orcid.org/0000-0002-3880-3058
-
Funding
Funding for this research was provided by:
Aalborg University Hospital
- License Information
-
More Information
Article History
Received: 7 December 2025
Accepted: 12 January 2026
First Online: 4 February 2026
Declarations
:
: Peter Vestergaard is head of research in the Steno Diabetes Center North Denmark funded by an unrestricted grant from the Novo Nordisk Foundation. Nicklas H. Rasmussen holds shares in Novo Nordisk, has lecture fees from Boehringer Ingelheim and travel expenses from UCB. Aksayan Arunanthy Mahalingasivam holds shares in Novo Nordisk. Asger Ahlmann Bech and Martin Grønbech Jørgensen has no conflict of interest.
: The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines, all applicable regulatory requirements, and the Declaration of Helsinki for biomedical research involving human participants. The trial was registered at ClinicalTrials.gov (NCT06745544), reported to the North Denmark Region Committee on Health Research Ethics (protocol no. N-20240025), and to the North Jutland Research Department (ID no. F2024-197). All data were collected and securely stored using the Research Electronic Data Capture (REDCap) system v.13.1.37.
: ChatGPT was used for optimizing the written academic English and grammar.
